PDCD1 and head and neck squamous cell carcinoma: A phase II trial of enoblituzumab plus the investigational anti-PD-1 retifanlimab or the investigational anti-PD-1 and anti-lymphocyte-activation gene 3 tebotelimab in HNSCC (NCT04634825) is currently underway.28